Canada Spends Logo

Explore our Budget 2026 analysis

Grant: Operating Grant - PA: Aging - Optimizing population health and wellness

University of Toronto

$100,000.00

Signaling of oAbeta through PrP and Fyn to Tau

FY 2013-14

Summary
The program is designed to close persistent knowledge gaps in our understanding of the most central molecular interactions underlying Alzheimer's disease (AD). The deposition of a small molecule, referred to as "Abeta", outside of brain cells and of so-called "Tau" molecules inside of brain cells is diagnostic of AD. It is believed that exposure of cells to Abeta initiates a toxic cascade of events that, ultimately, leads to changes in the biology of Tau in a process that may involve at least two other molecules, termed "PrP" and "Fyn". It has been difficult to evaluate this model because test animals engineered to reproduce the Abeta angle of AD consistently failed to also reproduce the Tau side of the human disease. Studies in cultured cells are more useful in this regard but, to our surprise, when we recently tested brain cells deficient for PrP, key characteristics of the abnormal Tau biology seen in AD were maintained. Based on these observations, we hypothesize that signaling from Abeta to Tau through PrP may play a role but is not sufficient to elicit the full Tau pathology characteristic for AD; another PrP-independent pathway of Abeta-to-Tau signaling must exist. The possibility to study this hypothesis emerged recently when we obtained access to both, the first AD mouse model known to exhibit Abeta-dependent Tau pathology and high-end tools for studying the molecular composition and molecular interactions within cells or tissues. We will manipulate the new AD mouse model so it cannot produce PrP or Fyn to gauge their relative contribution to Abeta-to-Tau signaling. We will use the high-end tools to identify changes to molecules within brain cells in response to Abeta which have the capacity to serve as selective markers for the early AD diagnosis. Finally, we will use these tools to uncover novel molecules which serve as missing links within the Abeta-to-Tau signaling pathway to reveal novel avenues for rational AD intervention.
Program
Operating Grant - PA: Aging - Optimizing population health and wellness
Location
Ontario, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database

As published

Id
309548
Name
Schmitt-Ulms Gerold
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Aging
Theme2
Biomedical
Prcname2
Molecular & Cellular Neurosciences - B
Projecttitle
Signaling of oAbeta through PrP and Fyn to Tau
Programtype2
Operating Grants
Orgnameinp2
University of Toronto
Cihramount2
$100,000
Cihrequipment2
$0
Programname2
Operating Grant - PA: Aging - Optimizing population health and wellness
Keyworddelim
Abeta; Alzheimer'S Disease; Animal Models; Diagnosis And Treatment; Disease Mechanism; Mass Spectrometry; Neurotoxicity; Prion Protein; Signaling; Tau
Abstract
The program is designed to close persistent knowledge gaps in our understanding of the most central molecular interactions underlying Alzheimer's disease (AD). The deposition of a small molecule, referred to as "Abeta", outside of brain cells and of so-called "Tau" molecules inside of brain cells is diagnostic of AD. It is believed that exposure of cells to Abeta initiates a toxic cascade of events that, ultimately, leads to changes in the biology of Tau in a process that may involve at least two other molecules, termed "PrP" and "Fyn". It has been difficult to evaluate this model because test animals engineered to reproduce the Abeta angle of AD consistently failed to also reproduce the Tau side of the human disease. Studies in cultured cells are more useful in this regard but, to our surprise, when we recently tested brain cells deficient for PrP, key characteristics of the abnormal Tau biology seen in AD were maintained. Based on these observations, we hypothesize that signaling from Abeta to Tau through PrP may play a role but is not sufficient to elicit the full Tau pathology characteristic for AD; another PrP-independent pathway of Abeta-to-Tau signaling must exist. The possibility to study this hypothesis emerged recently when we obtained access to both, the first AD mouse model known to exhibit Abeta-dependent Tau pathology and high-end tools for studying the molecular composition and molecular interactions within cells or tissues. We will manipulate the new AD mouse model so it cannot produce PrP or Fyn to gauge their relative contribution to Abeta-to-Tau signaling. We will use the high-end tools to identify changes to molecules within brain cells in response to Abeta which have the capacity to serve as selective markers for the early AD diagnosis. Finally, we will use these tools to uncover novel molecules which serve as missing links within the Abeta-to-Tau signaling pathway to reveal novel avenues for rational AD intervention.
Competitiondate
201403
Approvedterm2
1 yr 0 mth
Pinamesdelim
Schmitt-Ulms, Gerold
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $100,000~ $0~